Retrospective analysis of 118 patients with cutaneous T-cell lymphomas: a single-center experience
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F22%3A00013427" target="_blank" >RIV/00023736:_____/22:00013427 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/22:10445165 RIV/00064165:_____/22:10445165
Result on the web
<a href="https://doi.org/10.3389/fonc.2022.884091" target="_blank" >https://doi.org/10.3389/fonc.2022.884091</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fonc.2022.884091" target="_blank" >10.3389/fonc.2022.884091</a>
Alternative languages
Result language
angličtina
Original language name
Retrospective analysis of 118 patients with cutaneous T-cell lymphomas: a single-center experience
Original language description
Cutaneous T-cell lymphomas (CTCL) represent rare non-Hodgkin lymphomas (NHL) with an incidence less than 1 per 100,000 inhabitants. The most common type of CTCL is mycosis fungoides (MF), which represents approximately 60% of all CTCL, followed by Sézary syndrome (SS), approximately 5%. We retrospectively analyzed the outcome of 118 patients with MF (n=96) and SS (n=22) treated between the years 1998 and 2021 at the Charles University General Hospital in Prague, Czech Republic. In conclusion, our analysis of 118 real world cohort of consecutive CTCL patients treated at the single center confirmed the efficacy of immune response modifiers and underlines the urgent need for ample implementation of innovative agents and their combinations into earlier lines of therapy.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NV19-08-00144" target="_blank" >NV19-08-00144: Humanized patient-derived murine xenografts for experimental therapy of hematologic malignancies and for the study of in vivo acquired drug-resistance</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in oncology
ISSN
2234-943X
e-ISSN
—
Volume of the periodical
12
Issue of the periodical within the volume
[June]
Country of publishing house
CH - SWITZERLAND
Number of pages
9
Pages from-to
—
UT code for WoS article
000813892100001
EID of the result in the Scopus database
2-s2.0-85133452445